Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? Gilead Sciences, Inc. trades at $150.99 (market cap $182.40B), while State Street SPDR S&P Homebuilders ETF trades at $94.78 (market cap $1.49B). The key difference: Gilead Sciences, Inc. is far larger — about 122.4× State Street SPDR S&P Homebuilders ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| GILD | XHB | |
|---|---|---|
Market Cap | $182.40B | $1.49B |
Volume | 4,469,821 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $121.36 |
52-Week Low | $116.74 | $94.86 |
Typical Hold Time | 111 Days | 33 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.65, down 0.25% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but potential tailwinds from new housing affordability legislation and institutional interest.
The outlook for XHB is mixed, balancing sector-specific risks like rising rates against legislative support and valuation opportunities. Investment appeal hinges on a housing market recovery, with risks including economic sensitivity and inventory constraints. Sentiment is cautious but notes historical buying signals at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
